Zellweger-Like Contiguous Gene Deletion Syndrome

Zellweger-like contiguous gene deletion syndrome is a very rare, inherited condition that affects newborns and young infants. It happens when a small stretch of DNA is missing from the far end of the X chromosome (region Xq28). The missing piece usually includes two genes side-by-side: ABCD1 and BCAP31 (also called DXS1357E). Because both are gone together, the child’s body shows a pattern that looks like Zellweger spectrum disorder (a peroxisome biogenesis disease). Babies often have very poor muscle tone, feeding problems, serious liver disease with jaundice and cholestasis, poor growth, hearing problems, and brain white-matter problems. Sadly, the illness is often life-limiting in early infancy. This combined deletion is sometimes abbreviated CADDS (Contiguous ABCD1/DXS1357E Deletion Syndrome). Orpha+3NCBI+3PubMed+3

Zellweger-like contiguous gene deletion syndrome (CADDS) is a very rare genetic condition where a small stretch of the X chromosome is missing. That missing stretch removes more than one close-together gene at once—most importantly ABCD1 and BAP31 (DXS1357E). Because several genes are lost together, babies show a mixed picture that looks “Zellweger-like”: severe weakness (hypotonia), poor feeding, liver problems (cholestasis), poor growth, seizures, and early life-threatening illness. This happens because the lost genes disturb peroxisome-related functions (processing certain fats) and protein trafficking in cells, which harms the brain, liver, and other organs. CADDS is X-linked (mostly affects boys). It is different from classic Zellweger spectrum disorder (ZSD) caused by PEX genes, but the symptoms overlap; supportive care is similar, and cholic acid (CHOLBAM®) can help the liver and fat-soluble vitamin absorption in some patients. NCBI+4PubMed+4Global Genes+4

Why it looks “Zellweger-like.” When ABCD1 is deleted, very-long-chain fatty acids (VLCFAs) build up in the body because a peroxisome transporter is missing. When BCAP31 is missing, cells also struggle with protein trafficking in the endoplasmic reticulum. Together, these changes create a biochemical picture and clinical picture that strongly resembles Zellweger spectrum disorder, even though the root cause is a contiguous gene deletion and not the classic PEX-gene defects that cause Zellweger spectrum. NCBI+2PMC+2

---

Other names

• CADDS — Contiguous ABCD1–DXS1357E (BCAP31) Deletion Syndrome. PubMed+1

• Zellweger-like contiguous gene deletion syndrome — emphasizes the Zellweger-type appearance. Global Genes

• Distal Xq28 microdeletion including ABCD1 and BCAP31 — names the chromosome region. PubMed

• ABCD1/BCAP31 contiguous gene deletion — lists the key missing genes. PubMed

---

Types

Doctors think about “types” by what exact genes are deleted and how severe the illness looks:

1. Core CADDS (ABCD1 + BCAP31 deleted). This is the classic form with severe liver cholestasis, very poor tone, early feeding problems, and early death common. PubMed

2. Extended deletions (ABCD1 + BCAP31 + neighboring genes such as SLC6A8). When nearby genes are also missing, problems can be even more complex (for example, creatine transport defects). PubMed+1

3. BCAP31 deletion alone. This causes a severe X-linked neurodevelopmental syndrome, but without the same peroxisomal VLCFA profile. It overlaps clinically but is not classically “Zellweger-like.” PMC

4. ABCD1 deletion or mutation alone (X-linked adrenoleukodystrophy). This is a different disease that can present later and does not by itself explain the severe neonatal cholestasis typical of CADDS. NCBI

---

Causes

This is a genetic condition. The “causes” below are the practical reasons a deletion occurs or is detected, and the biological pathways that make symptoms appear.

1. A spontaneous (de novo) microdeletion at Xq28. Many families have no history; the deletion happens for the first time in the child. ScienceDirect

2. X-linked inheritance from a mother who carries the deletion. A mother can be a carrier with milder or no signs; sons are usually affected. PubMed

3. Non-allelic homologous recombination. Repetitive DNA sequences can misalign during egg or sperm formation, creating a missing piece. PubMed

4. Deletion includes ABCD1. Loss of ABCD1 blocks transport of VLCFAs into peroxisomes, causing toxic buildup. NCBI

5. Deletion includes BCAP31. Loss of BCAP31 disrupts ER protein trafficking and cell survival pathways, worsening neurodevelopment and liver disease. PMC

6. Combined loss of ABCD1 + BCAP31 produces a “synergy.” The combination is linked to neonatal cholestasis and death in the first year. PubMed

7. Occasional extension into SLC6A8. Loss of the creatine transporter adds brain energy problems. PubMed+1

8. X-inactivation effects in female carriers. Skewing can sometimes produce variable features in females. (Rare symptomatic females are reported.) PMC

9. Very-long-chain fatty acid accumulation. VLCFAs harm myelin, adrenal cortex, and liver. NCBI

10. Secondary peroxisomal dysfunction. Biochemical tests can look like Zellweger spectrum even though PEX genes are intact. PubMed

11. Poor myelination of brain white matter. This is tied to toxic lipid accumulation and cellular stress. PubMed

12. Mitochondria–ER stress from BCAP31 loss. This worsens cell survival in the liver and brain. PMC

13. Adrenal involvement from ABCD1 loss. The adrenal glands can be at risk because of VLCFA build-up. NCBI

14. Fetal growth restriction. Many babies are small at birth due to the genetic effect during pregnancy. Orpha

15. Severe neonatal hypotonia. Muscles are weak and floppy due to brain and muscle involvement. Orpha

16. Feeding failure. Poor tone and neurologic problems make feeding difficult. Orpha

17. Cholestasis with bile flow blockage. Liver cannot move bile normally; jaundice appears early. PubMed

18. Elevated liver enzymes and synthetic failure. Damage reduces clotting factor production and albumin. PubMed

19. Hearing loss. Sensorineural deafness is frequent because of inner-ear and neural injury. PubMed

20. Early infant death in severe cases. Outcomes are poor when both ABCD1 and BCAP31 are deleted. PubMed

---

Common symptoms and signs

1. Very poor muscle tone (hypotonia). Baby feels floppy and cannot hold the head up. This comes from brain white-matter problems and weak muscles. Orpha

2. Poor feeding and swallowing. Babies tire easily and may need tube feeding. Poor tone and brain involvement make coordination hard. Orpha

3. Jaundice and pale stools (cholestasis). The liver cannot move bile; skin looks yellow and stools may be light-colored. PubMed

4. Liver enlargement or failure. Doctors may feel a large liver; blood tests show damage. Severe cases may progress to liver failure. PubMed

5. Poor growth (failure to thrive). Babies gain weight slowly because feeding is difficult and the body is stressed. Orpha

6. Developmental delay. Milestones like rolling, sitting, and speaking are delayed because the brain’s wiring is affected. PubMed

7. Seizures. Abnormal brain activity can cause convulsions or staring spells. PubMed

8. Hearing loss. Inner-ear or nerve damage may cause sensorineural deafness; hearing aids may be needed. PubMed

9. Breathing problems. Weak tone and neurologic issues can lead to shallow or irregular breathing. PubMed

10. Irritability or lethargy. Babies may be unusually sleepy or hard to console, reflecting brain and liver disease. PubMed

11. Low body temperature or trouble keeping warm. Poor energy handling and low muscle tone reduce heat production. Orpha

12. Vision problems. Optic nerve or retinal issues may occur, and tracking may be poor. PubMed

13. Abnormal muscle reflexes. Reflexes can be reduced or sometimes brisk, depending on which pathways are affected. PubMed

14. Vomiting or reflux. Weak tone and slow gut movement can cause frequent spit-ups or vomiting. PubMed

15. Early infant death in severe cases. The combination of liver failure, infections, and neurologic problems can be overwhelming despite care. PubMed

---

Diagnostic tests

A) Physical examination

1. Newborn exam with growth charting. Doctors measure weight, length, and head size. Many babies are small from the start (intrauterine growth restriction). Orpha

2. Neurologic exam. The clinician checks tone, reflexes, and alertness. Poor tone and delayed responses raise concern. PubMed

3. Liver exam. Doctors feel for an enlarged liver and look for jaundice and scratch marks from itching due to cholestasis. PubMed

4. Hearing screening at birth. Newborn hearing checks often show reduced responses; this prompts formal audiology testing. PubMed

5. Ophthalmic exam. An eye doctor looks for optic nerve problems or retinal changes, which can occur in peroxisomal-like conditions. NCBI

B) “Manual” bedside tests and procedures

6. Feeding and swallow assessment. A speech-language pathologist watches bottle or breast feeds and may recommend thickened feeds or tube support. PubMed

7. Neonatal tone and posture scoring. Simple bedside scales document hypotonia and help track change over time. PubMed

8. Bedside developmental screening. Tools like the HINE or Bayley-based observations flag delays early for therapy referrals. PubMed

9. Bedside glucose checks. Sick infants with liver disease or poor feeding can have low sugar; quick checks guide urgent care. PubMed

C) Laboratory and pathological tests

10. Very-long-chain fatty acids (VLCFAs). Elevated C26:0 and abnormal C24/C22 and C26/C22 ratios are classic when ABCD1 is missing. This is a key biochemical clue for a “Zellweger-like” pattern. NCBI

11. Bile acids and liver panel. High conjugated bilirubin, high GGT or AST/ALT, and low albumin show cholestasis and reduced liver function. PubMed

12. Plasmalogens and peroxisomal markers. Some babies show abnormal plasmalogens or phytanic/pristanic acid levels, mimicking Zellweger spectrum. NCBI

13. Newborn metabolic screen review. Results may be nonspecific but can support further testing when abnormal. NCBI

14. Coagulation profile. INR/PT can be prolonged in cholestasis because vitamin K absorption is poor; this affects bleeding risk. PubMed

15. Endocrine panel (adrenal function). ABCD1 loss raises concern for adrenal involvement; cortisol and ACTH testing are checked if indicated. NCBI

16. Genetic microarray (CMA). Detects the microdeletion at Xq28 and shows which genes are missing. This is often the first genetic test to confirm a contiguous deletion. PubMed

17. Targeted gene testing / exome with CNV analysis. If CMA is unclear, exome sequencing with copy-number calling can show an ABCD1–BCAP31 deletion and whether nearby genes (like SLC6A8) are also missing. ScienceDirect

D) Electrodiagnostic tests

18. EEG. Checks for seizures or abnormal brain activity in hypotonic infants with spells or poor responsiveness. PubMed

19. Auditory brainstem response (ABR). Measures hearing pathway function; often abnormal in this syndrome. PubMed

20. Nerve conduction studies (when feasible). In selected cases, help assess peripheral nerve involvement related to VLCFA toxicity. NCBI

E) Imaging tests (additional key studies)

• Brain MRI with myelination assessment. Often shows hypomyelination or delayed myelination and other white-matter changes typical of “Zellweger-like” disorders. PubMed

• Abdominal ultrasound. Looks at liver size and bile ducts; supports the cholestasis evaluation. PubMed

Non-pharmacological treatments (therapies & other care)

1. Comprehensive care team & early intervention
   Create a team (neonatology, neurology, hepatology, nutrition, PT/OT/SLP, audiology, ophthalmology, genetics, palliative care) and start therapy as early as possible. Early, coordinated care improves comfort, feeding safety, infection prevention, and development even when the disease is severe. Family education on seizure first-aid, aspiration prevention, and home supports is essential. NCBI+1

2. Nutritional assessment with specialized feeding plans
   Frequent swallowing checks, safe-texture feeds, and calorie-dense formulas are used to prevent aspiration and support growth. If oral intake is unsafe or insufficient, temporary nasogastric feeds or a gastrostomy tube can be considered to reduce choking risk and stabilize weight. Fat-soluble vitamin monitoring is routine in cholestasis. NCBI

3. Low-phytanic-acid diet guidance
   Limiting foods rich in phytanic acid (certain dairy, ruminant fats, some fish) can reduce toxic fatty acid build-up that worsens peroxisomal disorders. Dietitians tailor plans to cultural foods and growth needs, with careful vitamin and mineral balancing. NCBI

4. Physical therapy (PT)
   Gentle range-of-motion, positioning, and postural support help prevent contractures, improve comfort, and support respiratory function when hypotonia is profound. Caregivers learn safe handling and stretching routines. NCBI

5. Occupational therapy (OT)
   OT focuses on feeding skills, hand function, seating, and daily care adaptations. Appropriate seating systems and splints may protect joints and reduce fatigue, making caregiving safer. NCBI

6. Speech-language therapy (SLP) for swallowing/communication
   SLP assesses swallow safety, recommends thickeners or positional strategies, and introduces early communication supports (eye-gaze boards, switches) to reduce frustration and aspiration risk. NCBI

7. Hearing management (audiology)
   Early hearing tests, hearing aids, or candidacy evaluation for cochlear implantation (for severe sensorineural loss) improve awareness of sound and caregiver bonding; timing depends on medical stability. NCBI

8. Vision care (ophthalmology & low-vision services)
   Regular exams detect retinal dysfunction and refractive errors. Low-vision strategies (contrast, lighting, high-contrast toys) maximize remaining vision and interaction. NCBI

9. Seizure safety planning
   Caregivers learn seizure recognition, positioning, and when to use prescribed rescue medicine. A written plan reduces emergency delays and improves home safety. NCBI

10. Airway clearance & respiratory therapy
    Positioning, suction, chest physiotherapy techniques, and aspiration prevention lower pneumonia risk in hypotonia and reflux. Home equipment (suction device, pulse oximeter) may be considered. NCBI

11. Immunization optimization
    Keeping routine vaccines current reduces preventable infections; RSV prophylaxis may be considered seasonally in eligible infants with severe neuromuscular or cardiopulmonary vulnerability. FDAaccessdata

12. Infection prevention at home
    Hand hygiene, breastfeeding support when possible, caregiver vaccination, and early evaluation of fevers are simple steps to reduce complications. NCBI

13. Reflux precautions
    Upright positioning after feeds, smaller frequent meals, and safe sleep positioning (per local infant sleep guidance) help lessen reflux-related aspiration. Medical therapy is added if needed. FDAaccessdata

14. Pain and spasticity positioning
    Supportive seating, gentle stretching, warm baths, and splints can ease discomfort and reduce tone-related pain before escalating to medicines. NCBI

15. Assistive technology & adaptive equipment
    Custom seating systems, bath supports, adapted utensils, and mobility aids reduce caregiver strain and improve participation in daily routines. NCBI

16. Genetic counseling for the family
    Explains X-linked inheritance, testing options for parents/siblings, recurrence risk, and supports for future pregnancies. Counseling also clarifies how CADDS differs from PEX-gene ZSD. PubMed+1

17. Psychosocial and palliative care
    Palliative care focuses on comfort, symptom control, and aligning treatments with family goals at every stage—not only end-of-life. It supports grief, stress, and complex decisions. NCBI

18. Home nursing and respite services
    Trained aides can help with feeding tubes, suction, seizure observation, and equipment—reducing hospitalizations and caregiver burnout. NCBI

19. Educational supports
    Individualized plans (when age-appropriate) add therapies in school settings and provide transportation, equipment, and communication supports. NCBI

20. Emergency care plan
    A one-page summary (diagnosis, key meds, allergy, seizure plan, aspiration risks) helps emergency teams act fast and safely. NCBI

---

Drug treatments

Important: No medicine “cures” CADDS. Drugs below are commonly used to treat complications (cholestasis, seizures, reflux, infections, spasticity, constipation). Doses must be individualized by clinicians, especially in fragile infants.

1. Cholic acid (CHOLBAM®)
   Class/Purpose: Primary bile acid; supports bile flow and fat-soluble vitamin absorption in peroxisomal disorders with liver disease.
   Typical dosing/time: Per FDA label, dose is weight-based (often 10–15 mg/kg/day in 1–2 doses; clinician adjusts to labs/growth).
   Mechanism: Replaces deficient primary bile acids, improves bile-dependent absorption, and may reduce toxic intermediates.
   Key cautions/side effects: Monitor liver tests; effect on extrahepatic symptoms not established. FDAaccessdata+3FDAaccessdata+3FDAaccessdata+3

2. Ursodeoxycholic acid (Ursodiol; ACTIGALL®/URSO®)
   Class/Purpose: Hydrophilic bile acid used for cholestasis in selected settings; sometimes used adjunctively.
   Dose: PBC label 13–15 mg/kg/day in divided doses (pediatric use is off-label and clinician-directed in cholestasis).
   Mechanism: Improves bile flow and reduces more toxic bile acids.
   Side effects: Diarrhea, pruritus changes; monitor LFTs. FDAaccessdata+1

3. Levetiracetam
   Class/Purpose: Broad-spectrum antiepileptic for seizures.
   Dose: Pediatric dosing is weight- and age-based per FDA labeling; titrated to effect and tolerability.
   Mechanism: Modulates synaptic vesicle protein SV2A to reduce neuronal hyperexcitability.
   Side effects: Somnolence, irritability; adjust for renal function. FDAaccessdata+2FDAaccessdata+2

4. Clobazam (ONFI® / sympazan®)
   Class/Purpose: Benzodiazepine adjunct for refractory seizures/spasms.
   Dose: Titrated by weight and response per label.
   Mechanism: GABA-A enhancement to raise seizure threshold.
   Side effects: Sedation, respiratory depression (esp. with opioids), tolerance. FDAaccessdata+2FDAaccessdata+2

5. Midazolam nasal spray (NAYZILAM®) – rescue
   Class/Purpose: Rapid benzodiazepine rescue for seizure clusters in eligible ages.
   Dose: Single intranasal 5 mg device; label limits frequency (no more than one episode every 3 days, ≤5/month).
   Mechanism: Fast GABA-A potentiation stops clusters outside hospital.
   Side effects: Sedation, respiratory depression; avoid in acute narrow-angle glaucoma. FDAaccessdata+3FDAaccessdata+3FDAaccessdata+3

6. Diazepam rectal gel / intranasal rescue (class representative)
   Purpose: Home rescue for prolonged seizures when intranasal midazolam is not used.
   Notes: FDA-labeled diazepam rescue products exist; prescribers choose per age, weight, and care plan.
   Risks: Sedation, respiratory depression; strict caregiver instructions essential. NCBI

7. Baclofen (oral solutions/granules such as LYVISPAH®, FLEQSUVY®, OZOBAX®)
   Class/Purpose: Antispasmodic for tone/pain management when spasticity evolves.
   Dose: Start low, titrate cautiously; withdrawal can be dangerous—do not stop abruptly.
   Mechanism: GABA-B agonist reduces spinal reflexes.
   Side effects: Sedation, hypotonia; watch swallowing safety. FDAaccessdata+2FDAaccessdata+2

8. Omeprazole (PRILOSEC®)
   Class/Purpose: Proton-pump inhibitor for GERD/erosive esophagitis that worsens feeding and aspiration risk.
   Dose: Weight-/indication-specific per label (pediatric dosing available for certain ages).
   Mechanism: Blocks gastric H+/K+-ATPase to reduce acid.
   Side effects: GI upset, rare hypomagnesemia with prolonged use; use the shortest effective duration. FDAaccessdata+2FDAaccessdata+2

9. Polyethylene glycol 3350 (MiraLAX® or Rx PEG solutions)
   Class/Purpose: Osmotic laxative for constipation from hypotonia/low intake/opioids.
   Dose: Label-guided dosing; ensure adequate fluids; avoid if obstruction suspected.
   Mechanism: Retains water in stool to improve transit.
   Side effects: Bloating; rare electrolyte issues if overused. FDAaccessdata+1

10. Amoxicillin (as needed for proven bacterial infections)
    Class/Purpose: Penicillin antibiotic when clinically indicated (e.g., otitis media).
    Dose: Weight-based per infection-specific recommendations; confirm local resistance.
    Mechanism: Inhibits bacterial cell wall synthesis.
    Side effects: Allergy including anaphylaxis; rash, diarrhea. Use only when bacterial infection is diagnosed. FDAaccessdata

11. Ceftriaxone (parenteral; when indicated)
    Class/Purpose: Broad-spectrum cephalosporin for serious infections per clinician judgment.
    Dose: Weight-based IV/IM per label and guidelines.
    Mechanism: Inhibits bacterial cell wall synthesis.
    Side effects: Biliary sludging, diarrhea; monitor jaundice in cholestasis. FDAaccessdata+1

12. Clonazepam
    Class/Purpose: Benzodiazepine anticonvulsant option in selected seizure types.
    Dose: Titrated slowly; monitor for sedation.
    Mechanism: GABA-A enhancement.
    Side effects: Sedation, drooling, respiratory depression with other depressants. FDAaccessdata

13. Fat-soluble vitamins (A, D, E, K) – prescription forms when needed
    Purpose: Correct deficiencies from cholestasis to support bones, eyes, immunity, and clotting.
    Note: Specific products/doses vary; clinicians follow levels and adjust carefully to avoid toxicity (particularly A and D). NCBI

14. Vitamin K (phytonadione) – when deficiency/coagulopathy suspected
    Purpose: Corrects impaired clotting from fat-soluble vitamin malabsorption.
    Note: Dose/route per clinician; monitor INR. NCBI

15. Cholestyramine (selected cases of pruritus)
    Class/Purpose: Bile-acid sequestrant for cholestatic itching if present.
    Considerations: Can bind other drugs/vitamins—time doses apart; not for obstructive jaundice without guidance. NCBI

16. Antipyretics/analgesics (acetaminophen; careful dosing)
    Purpose: Comfort for fever/pain; dosing must consider liver function and total daily limits.
    Note: Always dose by weight and under clinician supervision in infants. NCBI

17. Topical barrier creams (diaper/skin care)
    Purpose: Protect fragile skin; reduce breakdown from immobility or diarrhea.
    Mechanism: Physical barrier and moisture control. NCBI

18. Prokinetics/anti-reflux adjuncts (clinician-selected)
    Purpose: In refractory reflux with aspiration risk; choices individualized because of side-effect profiles.
    Note: Benefits must outweigh risks; close monitoring required. FDAaccessdata

19. Antipruritics/antihistamines (selected cases)
    Purpose: Symptomatic relief of itch affecting sleep/feeding in cholestasis; use cautiously due to sedation. NCBI

20. RSV prophylaxis (palivizumab) for eligible infants
    Class/Purpose: Monoclonal antibody to prevent severe RSV disease in high-risk infants (eligibility per local policy/season).
    Dose: Weight-based monthly during season.
    Side effects: Fever, injection-site reactions. FDAaccessdata+1

---

Dietary molecular supplements

Supplements should be supervised; evidence for disease-modification is limited or mixed.

1. DHA (docosahexaenoic acid)
   Lower DHA levels are common in peroxisomal disorders. Some studies suggest DHA may support retinal and neurologic function; others show limited benefit. Doses vary (often 50–100 mg/kg/day in pediatric studies), with monitoring for GI upset and bleeding risk when combined with anticoagulants. Families should understand goals are supportive, not curative. Nature+3American Academy of Neurology+3PubMed+3

2. Vitamin A
   Used to correct deficiency from cholestasis to support vision and immunity. Dosing is lab-guided to avoid toxicity (headache, vomiting, liver strain). Use prescription products when possible and recheck levels. NCBI

3. Vitamin D (D2/D3)
   Supports bone health when absorption is poor. Clinicians choose dose by level/age and may use higher, short-term repletion then maintenance. Monitor calcium, phosphorus, and ALP. NCBI

4. Vitamin E (water-miscible forms)
   Neuromuscular and retinal protection is theoretical; deficiency is common in cholestasis. Special water-miscible preparations improve absorption; dosing is weight-based with level checks. NCBI

5. Vitamin K
   If INR is elevated or bruising occurs, fat-soluble vitamin K supplementation (oral or parenteral) is used under lab guidance to restore clotting factor function. NCBI

6. Medium-chain triglyceride (MCT) oil
   MCTs are absorbed more easily in cholestasis. Small, frequent additions raise calories without overwhelming digestion; monitor tolerance and stool. NCBI

7. Essential fatty acid blend (balanced omega-3/6)
   In select cases, a carefully balanced blend prevents deficiency when long-chain fat handling is abnormal. Dietitians adjust amounts to avoid GI upset or growth issues. NCBI

8. Sodium supplementation (if cholestasis-related malabsorption/diuretics)
   Some infants need tailored electrolyte supplementation for growth; labs guide any sodium replacement to avoid fluid overload. NCBI

9. Zinc
   Deficiency worsens poor appetite and wound healing. Low levels are replaced with weight-based dosing; too much causes nausea and copper imbalance. NCBI

10. Carnitine (select cases)
    Used by some centers if documented secondary deficiency; benefits are uncertain in peroxisomal disease and must be individualized. Monitor for GI upset and fishy odor. NCBI

---

Immunity-booster / regenerative / stem-cell drugs

There are no FDA-approved regenerative or stem-cell therapies for CADDS/ZSD. Supportive biologics may reduce complications but do not change the genetic cause.

1. Palivizumab (RSV monoclonal prophylaxis) – may reduce severe RSV in eligible high-risk infants during season; monthly injections by weight. FDAaccessdata

2. Inactivated routine vaccines (programmatic) – not a “drug” for cure, but critical immune protection; schedules per country program/physician. NCBI

3. Seasonal influenza vaccine – annual inactivated vaccine decreases hospitalization risk. NCBI

4. IVIG (selected immunologic indications) – considered if specific antibody deficiency is proven; hospital-supervised infusion with monitoring. (Evidence is case-based in complex multisystem disease.) NCBI

5. Antimicrobial prophylaxis (case-by-case) – not a booster, but in infants with recurrent serious infections, specialists sometimes consider targeted prophylaxis; this weighs resistance risks carefully. NCBI

6. Erythropoiesis-stimulating agents/colony-stimulating factors (rare, lab-driven) – used only if specific cytopenias and indications exist; not disease-modifying for CADDS. NCBI

---

Surgeries/procedures (why they’re done)

1. Gastrostomy tube (G-tube) placement
   For unsafe or inadequate oral feeding, a G-tube provides reliable nutrition/medication delivery, reduces aspiration, and eases home care. NCBI

2. Cochlear implant evaluation/implantation
   In severe sensorineural hearing loss, implantation can improve sound awareness and caregiver interaction when hearing aids don’t help and the child is medically stable. NCBI

3. Hernia repair
   Abdominal wall weakness and chronic cough/constipation can lead to hernias; repair prevents incarceration and improves comfort. NCBI

4. Orthopedic soft-tissue releases
   For fixed contractures that impair care or cause pain, selective releases improve positioning and hygiene. NCBI

5. Feeding tube conversions (G-to-GJ) or fundoplication (selected cases)
   If reflux causes repeated aspiration despite maximal therapy, specialists may consider conversion to gastro-jejunal feeding or anti-reflux surgery after careful risk–benefit review. NCBI

---

Preventions (practical steps)

1. Keep vaccinations up-to-date; consider RSV prophylaxis if eligible. FDAaccessdata

2. Practice strict hand hygiene and limit exposure during respiratory virus seasons. NCBI

3. Swallow safety checks and reflux management to prevent aspiration. FDAaccessdata

4. Safe sleep and upright after-feed positioning per pediatric guidance. NCBI

5. Early treatment of fevers and infections; follow written emergency plan. NCBI

6. Regular labs (liver tests, fat-soluble vitamins, coagulation) to catch problems early. NCBI

7. Eye and hearing checks on schedule to optimize aids/therapy. NCBI

8. Physical therapy to prevent contractures and scoliosis progression. NCBI

9. Caregiver training for seizures, tube care, suction, and equipment. NCBI

10. Genetic counseling for family planning and testing at-risk relatives. PubMed

---

When to see doctors urgently

Seek immediate medical care for: breathing trouble, persistent vomiting or inability to feed, fever in a young infant, seizures lasting longer than the rescue plan allows or clusters not responding to rescue medicine, increasing jaundice/bleeding/bruising, severe lethargy, dehydration, or any sudden change in tone, color, or alertness. Regular scheduled visits with neurology, hepatology, nutrition, and therapy services are also important to adjust plans proactively. NCBI+1

---

What to eat & what to avoid

What to focus on: energy-dense formulas or breast milk as guided; MCT-enriched feeds if advised; adequate protein for growth; monitored fat-soluble vitamins (A, D, E, K); sufficient fluids and fiber to prevent constipation; small, frequent, safe-texture meals to limit reflux/aspiration. NCBI

What to limit/avoid: high-phytanic-acid foods (certain dairy/ruminant fats and some fish) when advised; large, fast meals; choking hazards; unmonitored herbal products; and prolonged fasting that worsens weakness and reflux. Always individualize with the clinical team and dietitian. NCBI

---

Frequently asked questions (FAQs)

1) Is CADDS the same as Zellweger syndrome?
No. CADDS is a contiguous gene deletion on Xq28 (ABCD1 + BAP31/DXS1357E) that produces a Zellweger-like picture. Classic Zellweger spectrum disorder (ZSD) is due to PEX gene defects. Symptoms overlap, but the genetics differ. PubMed+1

2) How rare is it?
Extremely rare—estimated far below 1 in a million. Most reports involve male infants because it is X-linked. Orpha

3) What causes the symptoms?
Loss of several neighboring genes disrupts peroxisomal lipid handling and protein trafficking, injuring liver and brain development and producing hypotonia, seizures, and cholestasis. PubMed

4) Is there a cure?
No gene-repair treatment exists yet. Care is supportive: nutrition, seizure control, cholestasis care, and infection prevention. NCBI

5) What medicine helps the liver and vitamin absorption?
Cholic acid (CHOLBAM®) is FDA-approved as adjunctive therapy for peroxisomal disorders including Zellweger spectrum (used by analogy in CADDS when liver disease and fat-soluble vitamin issues are present). FDAaccessdata

6) Does DHA supplementation help?
Evidence is mixed; some studies suggest benefits for vision/biomarkers, others do not. It can be tried under supervision with realistic goals. American Academy of Neurology+2ScienceDirect+2

7) Why restrict phytanic acid?
Peroxisomes break down branched-chain fatty acids like phytanic acid; limiting intake may reduce harmful accumulation. A dietitian guides safe restrictions. NCBI

8) What about seizures at home?
Families are taught a rescue plan (e.g., intranasal midazolam or other prescribed rescue) and when to call emergency services. FDAaccessdata

9) Can hearing or vision be helped?
Yes—prompt hearing aids or cochlear implants (when indicated) and low-vision supports can improve interaction and development. NCBI

10) Are steroids or stem cells useful?
No approved stem-cell or regenerative therapies exist for CADDS/ZSD at this time. Use is investigational only. NCBI

11) Will my other children be affected?
Genetic counseling explains X-linked inheritance, carrier testing, and options in future pregnancies. PubMed

12) Can surgery cure feeding problems?
Surgery does not cure CADDS, but a G-tube or anti-reflux procedure may make feeding safer and reduce aspiration in select cases. NCBI

13) How often should labs be checked?
Clinicians typically monitor liver enzymes, bilirubin, and fat-soluble vitamin levels regularly, and adjust treatments based on growth and symptoms. NCBI

14) What is the long-term outlook?
CADDS is usually severe with high early mortality, but individual courses vary. Early, supportive, family-centered care aims to maximize comfort and prevent complications. PubMed

15) Where can I read more?
See GeneReviews (Zellweger spectrum disorder), Orphanet, GARD, and the CHOLBAM FDA label in the references below. FDAaccessdata+3NCBI+3Orpha+3

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 07, 2025.